Compare INSM & STLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | STLA |
|---|---|---|
| Founded | 1988 | 2021 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2B | 23.4B |
| IPO Year | 2000 | 2014 |
| Metric | INSM | STLA |
|---|---|---|
| Price | $140.44 | $7.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 23 | 6 |
| Target Price | ★ $188.73 | $11.79 |
| AVG Volume (30 Days) | 2.1M | ★ 16.0M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.95% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $168.46 | $7.43 |
| Revenue Next Year | $65.97 | $3.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.40 | $7.07 |
| 52 Week High | $212.75 | $13.09 |
| Indicator | INSM | STLA |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 31.20 |
| Support Level | $139.81 | $7.07 |
| Resistance Level | $167.01 | $10.34 |
| Average True Range (ATR) | 6.70 | 0.21 |
| MACD | -0.57 | 0.03 |
| Stochastic Oscillator | 0.58 | 4.32 |
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.